Journal of Cancer Prevention

eISSN 2288-3657
pISSN 2288-3649
Fig. 1.

Download original image

Fig. 1. The potential application of lncRNAs in cancer diagnosis, prevention and therapy. These summarized lncRNAs in various types of cancer were categorized according to the application of biomarkers for diagnosis or prognosis. The lncRNAs written in red letters represents the biomarkers for diagnosis; blue letters, for prognosis; black letters, for diagnosis and prognosis. In addition, their correlations with sex hormones were presented: *lncRNAs implicated in estrogen; #lncRNAs implicated in androgen. lncRNA, long non-coding RNA; ZNF385D-AS2, zinc finger protein 385D antisense RNA 2; MIR4435-2HG, microRNA 4435-2HG; PTCSC3, papillary thyroid carcinoma susceptibility candidate 3; PART1, prostate androgen regulated transcript 1; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed gene 3; DANCR, Differentiation Antagonizing Non-Protein Coding RNA; DLEU2, deleted in lymphocytic leukaemia 2; HOTAIR, HOX transcript antisense RNA; ERINA, estrogen-inducible lncRNA; FAM83H-AS1, FAM83H antisense RNA 1; C2orf71, chromosome 2 open reading frame 71; TCL6, T Cell Leukemia/Lymphoma 6; ARLNC1, AR-regulated long noncoding RNA 1; PRCAT38, prostate cancer-related transcript 38.
J Cancer Prev 2021;26:98~109
© J Cancer Prev
Copyright © Korean Society of Cancer Prevention. All Rights Reserved. / Powered by INFOrang Co., Ltd